Cho Jae Hyun, Kim Seik, Song Yong Sang
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Chin Clin Oncol. 2018 Dec;7(6):58. doi: 10.21037/cco.2018.10.11.
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancy and is the seventh most common cancer among women worldwide. The primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT) is a standard treatment of advanced EOC. However, there are still several limitations, such as high recurrence rate and subsequent chemoresistance. To date, many studies have reported that neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) shows non-inferior survival outcome and is associated with less postoperative morbidity compared with PDS. Therefore, NACT-IDS might be an alternative treatment strategy in advanced EOC. Nevertheless, the efficacy of NACT-IDS and selection of patients who would gain benefit from NACT-IDS are still on debate. To date, several studies have been conducted to predict the response of NACT using various methods, such as imaging studies and molecular biology techniques. In this article, the optimal indications for NACT using various methods will be discussed.
上皮性卵巢癌（EOC）是妇科恶性肿瘤死亡的主要原因，也是全球女性中第七大常见癌症。先进行初次肿瘤细胞减灭术（PDS），随后进行辅助化疗（ACT）是晚期EOC的标准治疗方法。然而，仍存在一些局限性，如高复发率和随后的化疗耐药性。迄今为止，许多研究报告称，新辅助化疗（NACT）后进行中间型肿瘤细胞减灭术（IDS）显示出非劣效的生存结果，并且与PDS相比术后发病率更低。因此，NACT-IDS可能是晚期EOC的一种替代治疗策略。然而，NACT-IDS的疗效以及能从NACT-IDS中获益的患者选择仍存在争议。迄今为止，已经进行了多项研究，使用各种方法（如影像学研究和分子生物学技术）来预测NACT的反应。在本文中，将讨论使用各种方法进行NACT的最佳适应证。
